Inactive Instrument
Precision Therapeutics Inc Stock Nasdaq
Stocks
US74033P1003
Biotechnology & Medical Research
| Market Cap | 140M 123M 116M 106M 198M 13.43B 200M 1.39B 537M 6.85B 526M 515M 22.03B | P/E 2026 * |
-6.95x | P/E 2027 * | -110x |
|---|---|---|---|---|---|
| Enterprise Value | 140M 123M 116M 106M 198M 13.43B 200M 1.39B 537M 6.85B 526M 515M 22.03B | EV / Sales 2026 * |
2.32x | EV / Sales 2027 * | 0.32x |
| Free-Float |
94.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Precision Therapeutics Inc
| 1 day | -7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2026-02-08 | |
| Director of Finance/CFO | - | 2026-04-15 | |
Kyle Okamoto
PSD | President | - | 2026-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Handley
BRD | Director/Board Member | 66 | 2020-02-18 |
Charles Nuzum
CHM | Chairman | 78 | 2026-02-08 |
| Director/Board Member | 60 | 2020-07-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.56% | -8.33% | - | - | 140M | ||
| -0.14% | +4.33% | +9.88% | +31.73% | 47.97B | ||
| -1.69% | +1.48% | +50.57% | +34.53% | 44.5B | ||
| +2.56% | +7.34% | +382.17% | +594.81% | 43.93B | ||
| +0.24% | +2.85% | +9.78% | +89.54% | 41.03B | ||
| -0.62% | -1.11% | +4.70% | +46.02% | 29.85B | ||
| -0.28% | +1.07% | +26.83% | +152.91% | 17.27B | ||
| -0.46% | +1.20% | +26.90% | +42.21% | 15.3B | ||
| -2.21% | -4.70% | - | - | 14.82B | ||
| +3.37% | +9.21% | +9.93% | - | 15.34B | ||
| Average | -0.68% | +2.35% | +65.10% | +141.68% | 30B | |
| Weighted average by Cap. | +0.10% | +2.86% | +82.61% | +156.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 60.4M 53.03M 50.03M 45.59M 85.41M 5.79B 86M 599M 232M 2.95B 227M 222M 9.49B | 431M 379M 357M 326M 610M 41.33B 614M 4.28B 1.65B 21.1B 1.62B 1.58B 67.79B |
| Net income | -41.4M -36.35M -34.29M -31.25M -58.54M -3.97B -58.95M -410M -159M -2.03B -155M -152M -6.51B | -4.5M -3.95M -3.73M -3.4M -6.36M -431M -6.41M -44.62M -17.25M -220M -16.89M -16.53M -707M |
| Net Debt | - | - |
Employees
-
















